Payment overview · 2025
General Payments
$817.22
21 reported records · 12 companies
Healthcare provider profile · identity verified
Bianca Ramirez
Physician Assistants & Advanced Practice Nursing Providers|Nurse Practitioner|Family · IMPERIAL, CA · NPI 1609215649
Verified facts
What the public records show
CMS Open Payments records show Bianca Ramirez received $817.22 in general payments during 2025 across 21 reported records.
MDD US Operations, LLC accounted for 22.8% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 13 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Rexulti, Valtoco.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported QULIPTA as an associated drug or biological on 298617 records involving 58957 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Qulipta by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported UBRELVY as an associated drug or biological on 299803 records involving 61203 distinct recipient NPIs. Public Medicare Part D data also shows 42 claims for Ubrelvy by this doctor in 2024.
Janssen Biotech, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported XARELTO as an associated drug or biological on 24 records involving 23 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Xarelto by this doctor in 2024.
Neurelis, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported VALTOCO as an associated drug or biological on 16082 records involving 5567 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Valtoco by this doctor in 2024.
Otsuka America Pharmaceutical, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported REXULTI as an associated drug or biological on 160756 records involving 46288 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Rexulti by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| MDD US Operations, LLC | Unresolved — no canonical attribution shown | $186.19 | 22.8% | 7 | 2025 |
| Globus Medical, Inc. | Unresolved — no canonical attribution shown | $147.85 | 18.1% | 1 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $125.00 | 15.3% | 1 | 2025 |
| UROGEN PHARMA, INC. | Unresolved — no canonical attribution shown | $113.64 | 13.9% | 1 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $52.96 | 6.5% | 2 | 2025 |
| Neurocrine BioSciences, Inc. | Unresolved — no canonical attribution shown | $52.07 | 6.4% | 2 | 2025 |
| Alnylam Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $34.35 | 4.2% | 1 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $32.46 | 4.0% | 2 | 2025 |
| VERTEX PHARMACEUTICALS INCORPORATED | Unresolved — no canonical attribution shown | $22.76 | 2.8% | 1 | 2025 |
| Neurelis, Inc. |
Neurelis, Inc. exact · evidence 2025-02-20 |
$19.51 | 2.4% | 1 | 2025 |
| Janssen Biotech, Inc. | Unresolved — no canonical attribution shown | $16.41 | 2.0% | 1 | 2025 |
| Nalu Medical, Inc. | Unresolved — no canonical attribution shown | $14.02 | 1.7% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $817.22 | 21 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Senza Normalized: senza |
Device | Globus Medical, Inc. | $147.85 | 1 | 2025 |
Source payment records
|
|||||
| KISUNLA Normalized: kisunla |
Drug | Lilly USA, LLC | $125.00 | 1 | 2025 |
Source payment records
|
|||||
| ZUSDURI Normalized: zusduri |
Drug | UROGEN PHARMA, INC. | $113.64 | 1 | 2025 |
Source payment records
|
|||||
| Gocovri Normalized: gocovri |
Drug | MDD US Operations, LLC | $64.76 | 3 | 2025 |
Source payment records
|
|||||
| Qelbree Normalized: qelbree |
Drug | MDD US Operations, LLC | $59.12 | 2 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Otsuka America Pharmaceutical, Inc. | $52.96 | 2 | 2025 |
Source payment records
|
|||||
| INGREZZA Normalized: ingrezza |
Drug | Neurocrine BioSciences, Inc. | $52.07 | 2 | 2025 |
Source payment records
|
|||||
| OXLUMO Normalized: oxlumo |
Drug | Alnylam Pharmaceuticals Inc. | $34.35 | 1 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $32.46 | 2 | 2025 |
Source payment records
|
|||||
| JOURNAVX Normalized: journavx |
Drug | VERTEX PHARMACEUTICALS INCORPORATED | $22.76 | 1 | 2025 |
Source payment records
|
|||||
| VALTOCO Normalized: valtoco |
Drug | Neurelis, Inc. | $19.51 | 1 | 2025 |
Source payment records
|
|||||
| ERLEADA Normalized: erleada |
Drug | Janssen Biotech, Inc. | $16.41 | 1 | 2025 |
Source payment records
|
|||||
| Nalu Neurostimulation System Normalized: nalu neurostimulation system |
Device | Nalu Medical, Inc. | $14.02 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| REXULTI rexulti |
2025 | Rexulti | 2024 | 14 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| VALTOCO valtoco |
2025 | Valtoco | 2024 | 12 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | QULIPTA open payments reported associated product |
CMS Open Payments — General Payments 298617 supporting records · 58957 recipient NPIs · example record 1201352530 |
Qulipta · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | UBRELVY open payments reported associated product |
CMS Open Payments — General Payments 299803 supporting records · 61203 recipient NPIs · example record 1201352530 |
Ubrelvy · 2024 Exact normalized brand match · 1 Part D row |
42 | 11 |
| Janssen Biotech, Inc. Exact reporting entity; no affiliate inference |
2025 | XARELTO open payments reported associated product |
CMS Open Payments — General Payments 24 supporting records · 23 recipient NPIs · example record 1174259978 |
Xarelto · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
| Neurelis, Inc. Exact reporting entity; no affiliate inference |
2025 | VALTOCO open payments reported associated product |
CMS Open Payments — General Payments 16082 supporting records · 5567 recipient NPIs · example record 1219183925 |
Valtoco · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| Otsuka America Pharmaceutical, Inc. Exact reporting entity; no affiliate inference |
2025 | REXULTI open payments reported associated product |
CMS Open Payments — General Payments 160756 supporting records · 46288 recipient NPIs · example record 1227267708 |
Rexulti · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Memantine Hcl | Memantine Hcl | 1006 | 248 |
| Gabapentin | Gabapentin | 893 | 246 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 662 | 154 |
| Clopidogrel | Clopidogrel Bisulfate | 490 | 114 |
| Levetiracetam | Levetiracetam | 480 | 105 |
| Atorvastatin Calcium | Atorvastatin Calcium | 432 | 129 |
| Donepezil Hcl | Donepezil Hcl | 376 | 99 |
| Meloxicam | Meloxicam | 321 | 114 |
| Lidocaine | Lidocaine | 274 | 88 |
| Baclofen | Baclofen | 268 | 74 |
| Pregabalin | Pregabalin | 257 | 91 |
| Trazodone Hcl | Trazodone Hcl | 238 | 65 |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 217 | 49 |
| Tramadol Hcl | Tramadol Hcl | 217 | 67 |
| Quetiapine Fumarate | Quetiapine Fumarate | 212 | 49 |
| Amitriptyline Hcl | Amitriptyline Hcl | 185 | 46 |
| Diclofenac Sodium | Diclofenac Sodium | 168 | 61 |
| Namzaric | Memantine Hcl/Donepezil Hcl | 148 | 37 |
| Topiramate | Topiramate | 147 | 34 |
| Divalproex Sodium | Divalproex Sodium | 142 | 30 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 131 | 39 |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 125 | 46 |
| Memantine Hcl Er | Memantine Hcl | 112 | 29 |
| Ibuprofen | Ibuprofen | 91 | 33 |
| Prednisone | Prednisone | 86 | 58 |
| Amantadine | Amantadine Hcl | 85 | 13 |
| Escitalopram Oxalate | Escitalopram Oxalate | 83 | 22 |
| Sumatriptan Succinate | Sumatriptan Succinate | 79 | 19 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 78 | 20 |
| Lamotrigine | Lamotrigine | 77 | 13 |
| Nurtec Odt | Rimegepant Sulfate | 75 | 19 |
| Carbamazepine | Carbamazepine | 70 | 18 |
| Entacapone | Entacapone | 67 | 15 |
| Meclizine Hcl | Meclizine Hcl | 67 | 30 |
| Tizanidine Hcl | Tizanidine Hcl | 60 | 15 |
| Risperidone | Risperidone | 59 | 12 |
| Morphine Sulfate Er | Morphine Sulfate | 55 | 12 |
| Simvastatin | Simvastatin | 54 | 15 |
| Primidone | Primidone | 53 | 15 |
| Aptiom | Eslicarbazepine Acetate | 50 | 13 |
| Oxcarbazepine | Oxcarbazepine | 50 | suppressed |
| Buprenorphine | Buprenorphine | 48 | 17 |
| Phenobarbital | Phenobarbital | 48 | suppressed |
| Eliquis | Apixaban | 46 | 16 |
| Carbidopa-Levodopa Er | Carbidopa/Levodopa | 45 | 11 |
| Celecoxib | Celecoxib | 44 | 14 |
| Ubrelvy | Ubrogepant | 42 | 11 |
| Naproxen | Naproxen | 39 | 16 |
| Sertraline Hcl | Sertraline Hcl | 39 | suppressed |
| Fentanyl | Fentanyl | 36 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 36 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 34 | 13 |
| Aimovig Autoinjector | Erenumab-Aooe | 32 | 11 |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 30 | suppressed |
| Clonazepam | Clonazepam | 29 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 29 | suppressed |
| Ondansetron Odt | Ondansetron | 29 | suppressed |
| Hydromorphone Hcl | Hydromorphone Hcl | 27 | suppressed |
| Movantik | Naloxegol Oxalate | 27 | suppressed |
| Rivastigmine | Rivastigmine | 26 | 11 |
| Alprazolam | Alprazolam | 24 | 18 |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 22 | suppressed |
| Megestrol Acetate | Megestrol Acetate | 21 | suppressed |
| Mirtazapine | Mirtazapine | 19 | suppressed |
| Omeprazole | Omeprazole | 17 | suppressed |
| Divalproex Sodium Er | Divalproex Sodium | 15 | suppressed |
| Lacosamide | Lacosamide | 15 | suppressed |
| Methadone Hcl | Methadone Hcl | 14 | suppressed |
| Rexulti | Brexpiprazole | 14 | suppressed |
| Xarelto | Rivaroxaban | 14 | suppressed |
| Qulipta | Atogepant | 12 | suppressed |
| Valtoco | Diazepam | 12 | suppressed |
| Brilinta | Ticagrelor | 11 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 11 | suppressed |
| Icosapent Ethyl | Icosapent Ethyl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $817.22 · 21 records | MDD US Operations, LLC | ERLEADA, Gocovri, INGREZZA, JOURNAVX, KISUNLA, Nalu Neurostimulation System, OXLUMO, Qelbree, REXULTI, Senza, VALTOCO, VRAYLAR, ZUSDURI | 5 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Rexulti play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error